Risk-Enhancing Factors for ASCVD Risk Assessment
The most recent risk-enhancing factors from the 2019 ACC/AHA guidelines include family history of premature ASCVD, primary hypercholesterolemia, metabolic syndrome, chronic kidney disease, chronic inflammatory conditions, premature menopause/pregnancy complications, high-risk ethnicities, and specific lipid biomarkers (elevated triglycerides, high-sensitivity CRP, lipoprotein(a), apolipoprotein B, and ankle-brachial index <0.9). 1
Complete List of Risk-Enhancing Factors
The 2019 cholesterol guidelines 1 systematically identified these factors to refine risk assessment in borderline (5% to <7.5%) and intermediate-risk (≥7.5% to <20%) patients:
Traditional Risk Enhancers:
- Family history of premature ASCVD: Males <55 years, females <65 years
- Primary hypercholesterolemia: LDL-C 160-189 mg/dL (4.1-4.8 mmol/L) or non-HDL-C 190-219 mg/dL (4.9-5.6 mmol/L)
- Metabolic syndrome: Requires 3 of 5 criteria (increased waist circumference, triglycerides >175 mg/dL, elevated blood pressure, elevated glucose, low HDL-C <40 mg/dL in men or <50 mg/dL in women)
- Chronic kidney disease: eGFR 15-59 mL/min/1.73 m² with or without albuminuria (excluding dialysis/transplant patients)
Condition-Specific Enhancers:
- Chronic inflammatory conditions: Psoriasis, rheumatoid arthritis, or HIV/AIDS
- Women-specific factors: Premature menopause (before age 40), preeclampsia, or other pregnancy-associated conditions
- High-risk race/ethnicities: Particularly South Asian ancestry
Lipid and Biomarker Enhancers (if measured):
- Persistently elevated triglycerides: ≥175 mg/dL (optimally 3 determinations)
- High-sensitivity CRP: ≥2.0 mg/L
- Lipoprotein(a): ≥50 mg/dL or ≥125 nmol/L (especially relevant with family history of premature ASCVD)
- Apolipoprotein B: ≥130 mg/dL (particularly useful when triglycerides ≥200 mg/dL)
- Ankle-brachial index: <0.9
Clinical Application Algorithm
When to use risk enhancers 2, 1:
- Calculate 10-year ASCVD risk using Pooled Cohort Equations for adults 40-75 years
- If risk is borderline (5% to <7.5%) or intermediate (≥7.5% to <20%), assess for risk-enhancing factors
- Presence of ≥1 risk enhancer favors initiating or intensifying statin therapy
- If uncertainty persists after considering risk enhancers, coronary artery calcium scoring provides additional risk stratification
Evidence Quality and Prevalence
Recent data demonstrates that 77% of U.S. adults have at least one risk-enhancing factor, and 28% have three or more 3. The most prevalent are elevated high-sensitivity CRP (49.6%), metabolic syndrome (48.3%), and hypertriglyceridemia (18.9%) 3.
Important caveat: While individual risk enhancers modestly improve risk prediction, the simultaneous presence of multiple risk enhancers (≥3 factors) provides more substantial improvements in discrimination and reclassification 4. This supports the guideline approach of considering the totality of risk enhancers rather than relying on any single factor.
Practical Pitfalls
The guidelines emphasize that risk enhancers should guide clinician-patient discussion rather than serve as absolute treatment thresholds 2. The Pooled Cohort Equations may overestimate or underestimate risk in certain populations 2, making risk enhancers particularly valuable for individualizing assessment. However, evidence shows inconsistent association between risk enhancers and actual statin use in clinical practice, particularly in the borderline-risk category 3, suggesting underutilization of this guideline recommendation.